Clinical Trials Logo

Filter by:
NCT ID: NCT05499091 Recruiting - Genetic Disease Clinical Trials

Functional Study to Indentify Genetic Etiology of Rare Diseases - ORIGIN

ORIGIN
Start date: October 10, 2022
Phase: N/A
Study type: Interventional

Next generation sequencing (NGS) allows some better diagnostic results, particularly, in the rare diseases field. At a twenty five percent rate, those exams highlight some variants which are not yet described in human pathology. The relationship between a variant found inside a candidate gene and a pathology, is able to be confirmed by functional studies at a protein level. This study aims to build a biological collection to feed further functional studies to confirm the relationship between NGS identified variants, and the clinical signs and symptoms.

NCT ID: NCT05499078 Recruiting - Dry Nose Clinical Trials

Pilot Study to Assess Performance and Safety of SULFEX 13081.22 Nasal Spray in Patients With Dry or Irritated Nose

Start date: September 2, 2022
Phase: N/A
Study type: Interventional

As the medical device is CE marked, the objective of this study is to provide performance and safety data on SULFEX 13081.22 nasal spray as close as possible to the routine care.

NCT ID: NCT05498883 Recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

Quality of Life Evaluation With the SRI Questionnaire of ALS Patient With Non-invasive Ventilation

Quality EvALS
Start date: September 13, 2022
Phase: N/A
Study type: Interventional

This study aims to measure the quality of life of ALS patients by the SRI questionnaire, in two distinct patient groups : Patient requiring initiation of NIV, and patients 24 hours dependent on NIV This study also seeks to assess the quality of life of the caregivers with the Zarit Burden interview in those two populations

NCT ID: NCT05498831 Completed - Acute Pain Clinical Trials

Evaluation of a New Pain Management Protocol Involving Intranasal Sufentanil in the Emergency Room.

SUURGE
Start date: August 9, 2022
Phase:
Study type: Observational

Until now, the Mulhouse emergency department used a protocol for severe pain based on morphine titration. In order to relieve patients' pain more quickly, a new protocol was implemented based on the use of intranasal sufentanil. The primary objective of the study is to prospectively assess the efficacy of the new pain management protocol implemented in the emergency department and based on intranasal sufentanil in combination with paracetamol and codeine for pain of moderate intensity and intranasal sufentanil in combination with paracetamol followed by morphine titration for severe pain. This new pain management protocol has been updated as part of the upcoming French High Authority for Health hospital certification, for which pain management is one of the priority criteria. This research does not change the routine care given to the patient.

NCT ID: NCT05498532 Not yet recruiting - Clinical trials for Stricture of Pelviureteric Juncture

Functional MRI Evaluation in Pyeloureteral Junction Syndrome in Children

Start date: September 1, 2022
Phase:
Study type: Observational

Pyelo-ureteral junction syndrome is the most common urological abnormality in children. Functional MRI has been evaluated several times, and had shown good correlation with scintigraphy, but tends to over estimate results. Moreover, those studies included a small number of cases. Its sensitivity to detect crossing polar vessel is limited. We aimed to evaluate, in patients between 0 and 1 year old, the correlation between MRI and scintigraphy differential renal function. Our secondary objectives are : evaluation of MRI performances to detect polar vessel ; comparison of surgery times depending of MRI only realisation or MRI and scintigraphy realisation.

NCT ID: NCT05498428 Recruiting - Clinical trials for Carcinoma, Non-small-Cell Lung

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

PALOMA-2
Start date: November 11, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation [SC-CF]) in combination treatment (all cohorts except Cohort 4) and to characterize the safety of amivantamab SC-CF (Cohort 4).

NCT ID: NCT05497947 Completed - Swallowing Disorder Clinical Trials

Evaluation of the French Translation of Swallowing (SOAL-VF) Patient Reported Outcomes (PRO) After Total PharyngoLaryngectomy

SOAL-VF
Start date: July 3, 2021
Phase:
Study type: Observational

A monocentric study to evaluate the french translation of Swallowing (SOAL-VF) Patient Reported Outcomes (PRO) after Total PharyngoLaryngectomy

NCT ID: NCT05496998 Recruiting - Clinical trials for Mitral Regurgitation

Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial

APOLLO-EU
Start date: February 7, 2023
Phase: N/A
Study type: Interventional

Evaluate the safety and efficacy of Medtronic Intrepid™ TMVR TF System in patients with moderate-to-severe or severe symptomatic mitral regurgitation, or moderate symptomatic mitral regurgitation combined with mitral stenosis in the presence of MAC who, by agreement of the local site multidisciplinary heart team experienced in mitral valve therapies, are unsuitable for treatment with approved transcatheter repair or surgical mitral valve intervention.

NCT ID: NCT05496556 Recruiting - Clinical trials for Non-small Cell Bronchopulmonary Carcinoma at Stage IV and Benefiting From First-line Treatment According to Current French Recommendations

Influence of Food Preferences on the Occurrence of Undernutrition in Treated Patients for Bronchopulmonary Carcinoma Non-small Cell Stage IV

ONCOGOU
Start date: November 1, 2023
Phase: N/A
Study type: Interventional

The study will be offered to patients with non-small cell lung carcinoma diagnosed at stage IV and receiving first-line treatment. The patient will benefit from a complete assessment at inclusion (clinical exam, imagery, biological exam, dietary consultation, test LFQP. At the end of this 1st evaluation, patients in whom the diagnosis of undernutrition is made will benefit from dietary management with personalized advice that will take into account the symptoms of cancer, the possible side effects of treatments as well as the social environment. Every two cures, i.e. every 4 to 6 weeks, these examens will be performed until the occurrence of an event (progression of the disease according to the RECIST criteria, death or change of therapeutic line). At the end of these assessments, patients will benefit from dietary management with a readjustment of personalized advice that will take into account the difficulties highlighted during the assessment.

NCT ID: NCT05495932 Recruiting - Asthma Clinical Trials

Mepolizumab Pharmacokinetics Among Patients With Severe Asthma

CESAM
Start date: November 15, 2022
Phase: N/A
Study type: Interventional

Asthma is a chronic disease characterized by inflammation and obstruction of the airways. Identification of the mechanisms of action of corticosteroids has made it possible to define the type 2 inflammation present in nearly 80% of patients with asthma. Monoclonal antibodies (MAb) in severe asthma target type-2 inflammation. Mepolizumab is a humanized IgG1 (immunoglobulin gamma-1) kappa subclass monoclonal antibody directed specifically against interleukin 5 (IL-5). It acts specifically on eosinophil homeostasis, with IL-5 being a key interleukin in eosinophil maturation. The investigators propose to measure the concentrations of mepolizumab in the serum of asthmatic patients treated with this mAb. The investigators hypothesize that the individual pharmacokinetics (PK) of mepolizumab may differ between clinical responders and non-responders.